title: Chimeric antigen receptor T cell treatment in hematologic malignancies.
abstract: Adoptive transfer of T cells that have genetically engineered chimeric antigen receptors (CARs) is an encouraging treatment modality in the hematological malignancies. These T cells are capable of selectively recognizing tumor-associated antigens. There are a variety of reported, as well as ongoing studies on the utilization of CAR-T cells in the treatment of leukemia, myeloma, as well as B and T cell lymphomas. In this review, we aimed to highlight current understanding of this promising treatment modality, including its efficacy and adverse effects.
authors.affiliation: School of Medicine, Department of Internal Medicine, Division of Hematology, Hacettepe University, Ankara, Turkey. Electronic address: hgoker1@yahoo.com.
authors.forename: Hakan
authors.initials: H
authors.lastname: Goker
authors.affiliation: School of Medicine, Department of Internal Medicine, Division of Hematology, Hacettepe University, Ankara, Turkey.
authors.forename: Umit Yavuz
authors.initials: UY
authors.lastname: Malkan
authors.affiliation: School of Medicine, Department of Internal Medicine, Division of Hematology, Hacettepe University, Ankara, Turkey.
authors.forename: Haluk
authors.initials: H
authors.lastname: Demiroglu
authors.affiliation: School of Medicine, Department of Internal Medicine, Division of Hematology, Hacettepe University, Ankara, Turkey.
authors.forename: Yahya
authors.initials: Y
authors.lastname: Buyukasik
mesh_terms: D000818:Animals; D019337:Hematologic Neoplasms / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D011948:Receptors, Antigen, T-Cell